Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Stocks Near 52-Week Lows Worth Buying

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to the downside, just as we often do when the market reacts to the upside.

Here's a look at three fallen angels trading near their 52-week lows that could be worth buying.

All or nothing
This week I'll start by welcoming a microcap biotechnology company to my CAPS portfolio that I had previously never been fond of in the stem cell sector.

Aastrom Biosciences (Nasdaq: ASTM  ) has been one of the few exceptions in the biotech sector that hasn't had a great year. Since releasing phase 2 clinical data results on its critical limb ischemia (CLI) drug, ixmyelocel-T, in November 2011, the stock has lost close to half its value. Blame that partly on continued cash burn, as well as the fact that regulations governing the stem cell sector have been restrictive for many years. So much so that, as my Foolish colleague Rich Smith reminded us in May, Geron (Nasdaq: GERN  ) , previously a leading name in stem cell research, completely abandoned its stem cell program last year.

Getting back to Aastrom, what intrigues me is the positive results attributed to its phase 2 trial for CLI. The drug, which is really targeted at the most severe form of peripheral artery disease, works by drawing a patient's stem cells, incubating them at Aastrom's headquarters and spurring adult stem cell growth, and then reinjecting them to promote healing. The phase 2 study showed a 62% reduction in the risk of treatment failure and similar tolerability to the placebo, and, most important, the results were statistically significant not because of chance, but because the treatment pathway worked. Plenty of kinks to work out in phase 3, including funding, but I feel the price is finally right to start looking at Aastrom Biosciences.

Treat this stock like royalty
Most semiconductor companies find themselves at the mercy of the economy or a tech cycle shift every few years, and this has been the year that CEVA (Nasdaq: CEVA  ) , an Israeli-based provider of intellectual property used in 2G and 3G handsets, has felt the pinch.

Nokia (NYSE: NOK  ) , one of CEVA's largest customers, has struggled mightily with its rollout of a new line of smartphones, while also seeing unit sales decline on its lower-margin 2G handsets as a growing set of middle-class consumers in China have put off their purchases in favor of newer 3G technology. With CEVA's bread-and-butter in the past being its 2G royalties, clearly a drop-off in total handset sales is bound to hurt.

What should be kept in perspective is the fact that CEVA has 3G royalties geared toward smartphones and is merely caught in the midst of an industrywide tech cycle transition. Its deals with other vendors outside of Nokia will come into play moving forward and allow its royalty stream to stay consistent. I'd also like to note that CEVA has an incredible $6 in cash per share with no debt on its balance sheet – much of that owing to its minimal cost structure. This is the type of company that should rack up relatively predictable profits in good and bad times and I feel now is the time to treat CEVA like royalty.

Ask your server
The great thing about taking three steps forward and two steps back is that, at some point, you're going to come out ahead. While no investment is a sure thing, I'm beginning to think this statement fits server technology company Super Micro Computer (Nasdaq: SMCI  ) pretty well.

Mainline information technology spending has been weak for about a year now, but at some point large telecoms and big businesses are going to need to step up to improve their infrastructure -- Super Micro could be one of those beneficiaries. But, as a daily double, Super Micro is also a play on the rapidly growing cloud-computing sector. Its cloud-based servers could see rapid growth in big data centers, but, just like in its most recent quarter, it will need to deal with wild hard-drive price swings.

What Super Micro has on its side is a rich history of being profitable and a bare-bones valuation of less than nine times forward earnings. Super Micro will deal with the normal ebb and flow of the tech cycle, but as long as it remains profitable, it should be able to move forward three steps each time.

Foolish roundup
This week's trio is akin to the turtle versus the hare. Although the hare got off to a quick start, these three companies offer good longer-term potential if you're willing to accept the natural ebb and flow associated with each business.

I'm so confident that these three names will bounce off their lows that I'm going to make a CAPScall of outperform on each one.

Cloud-computing isn't the only technological revolution currently under way. Find out what technology and what trio of companies our team at Stock Advisor feels could lead the next Industrial Revolution, for free, by clicking here to get your copy of this latest special report.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that's always on the lookout for a good deal.

Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 09, 2012, at 11:48 AM, maniladad wrote:

    I took a quick look at that Phase 2 study from Aastrom as part of my evaluation of Cytori. It seems to me to be a very sloppy bit of work with, for example, lots of patients dropping out of the study and end-points that seem to be picked out of the air after the data was already collected. One minor thing was that two (I think) of the subjects in the treatment group were dropped because the physician was unable to obtain an adequate bone marrow aspiration. Another specimen was lost because of a mishap, a break in sterile technique as I recall, in the processing of the marrow sample. Bone marrow aspiration is not a pleasant procedure and a patient doesn't want to be told, "I'm sorry but we have to do that again because the company processing your specimen messed it up." Cytori has one advantage in that the specimen is processed right at the hospital, in the operating suite if desired, and is available within minutes, as opposed to about 2 weeks delay while the marrow is incubated with Aastrom. Plus it may be (don't think it's been conclusively demonstrated yet) that cells obtained from fat may be more effective than cells obtained from bone marrow. Finally, comparing the two companies, it appears that the management at Cytori really has a clear vision about where they are taking the company while Aastrom seems to be, like their clinical study, a bit sloppy. All in all I'm more inclined to go with Cytori but as I write this their stock has plummeted abut 7% this morning and I don't know why. Aastrom also seems to be taking a beating this morning. Not a good day to be invested in stem cell research, it seems.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2049347, ~/Articles/ArticleHandler.aspx, 10/24/2016 10:48:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,230.84 85.13 0.47%
S&P 500 2,151.30 10.14 0.47%
NASD 5,303.10 45.70 0.87%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 10:30 AM
CEVA $31.50 Up +0.70 +2.27%
CEVA CAPS Rating: ***
GERN $2.16 Up +0.04 +1.65%
Geron CAPS Rating: ***
NOK $4.96 Up +0.04 +0.81%
Nokia CAPS Rating: **
SMCI $21.45 Down -0.01 -0.05%
Super Micro Comput… CAPS Rating: **
VCEL $2.40 Down -0.05 -2.04%
Vericel CAPS Rating: *